Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder characterised by a combination of parkinsonism, cerebellar ataxia and autonomic dysfunction. Clinical assessment ...
The multiple system atrophy clinical trial analysis report delivers important insights into ongoing research of 24+ pipeline multiple system atrophy drugs, clinical strategies, upcoming therapeutics, ...
Biotechnology firm Tiziana Life Sciences Ltd. TLSA on Friday revealed promising quantitative PET imaging results from the third patient participating in its Phase 2 clinical trial. The ongoing study ...
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, researchers presented details on a new SERCA inhibitor ...
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, researchers presented details on a new SERCA inhibitor ...
Could an anomaly in the developing brain explain motor difficulties occurring decades later in people with rare movement disorders? These are the genetics being investigated by researchers at ...
α-synuclein is a neuronal protein involved in functions like vesicle trafficking and neurotransmitter release. It is typically found in abundance in a healthy brain. However, the aggregation of ...
Multiple system atrophy Parkinsonian type (MSA-P) is a rare neurodegenerative disease that progresses over time. It can cause problems with movement and coordination, digestion, bladder control, ...
In March 2016, Ian Fyfe, MD, published an article, “ Cerebellar Atrophy Has Disease-Specific Patterns," in the journal Nature Reviews Neurology. (Cerebellar means “of the cerebellum” and is the sister ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results